Abstract: The present invention relates to compositions comprising mesenchymal stem cells (MSC) useful for producing pharmaceutical formulation to treat musculoskeletal conditions, including joint degeneration, tendon and ligament laxity or rupture, and muscle conditions. The present invention relates to the field of regenerative medicine, namely formulating improved compositions for the treatment of musculoskeletal conditions, including joint degeneration, tendon and ligament laxity or rupture, and muscle conditions, having a positive impact on pharmaceutical formulations containing mesenchymal stem cells (MSCs), providing the enhancement of MSCs viability upon cryopreservation, MSCs stability during transportation and manipulation, and MSCs therapeutic efficacy of the final formulations.

Abstract: The present invention relates to a method for producing hydroxyapatite-bioglass macroporous material, to said materials, and to medical devices thereof. The method comprises a step of preparation of an aqueous suspension of hydroxyapatite and bioglass with a porogenic agent, and subsequent sintering to achieve a macroporous biomaterial. The macroporous structure of these materials enhances blood vessels and bone cells migration, allowing bone growth through the interior of the bone substitute, thereby increasing the rate of formation of new bone at the site of implantation. Therefore, these materials are advantageously used to produce medical devices, such as bone grafts that resemble the mineral phase of natural bone showing improved mechanical strength and osteoconductivity. The biomaterials of the present invention are applicable in the medical area, in particular in bone regeneration and reparation techniques as bone grafts.

Abstract: The present invention relates to compositions comprising mesenchymal stem cells (MSC) useful for producing pharmaceutical formulation to treat musculoskeletal conditions, including joint degeneration, tendon and ligament laxity or rupture, and muscle conditions. The present invention relates to the field of regenerative medicine, namely formulating improved compositions for the treatment of musculoskeletal conditions, including joint degeneration, tendon and ligament laxity or rupture, and muscle conditions, having a positive impact on pharmaceutical formulations containing mesenchymal stem cells (MSCs), providing the enhancement of MSCs viability upon cryopreservation, MSCs stability during transportation and manipulation, and MSCs therapeutic efficacy of the final formulations.